Press Detail

Biotest AG: Biotest AG opens 12th plasma collection centre in the Czech Republic

News: Biotest AG / Key word(s): Miscellaneous
Biotest AG: Biotest AG opens 12th plasma collection centre in the Czech Republic
06.09.2022 / 07:00 CET/CEST
The issuer is solely responsible for the content of this announcement.




Biotest AG opens 12th plasma collection centre in the Czech Republic


  • 32 plasma collection stations in Europe to secure the plasma supply in the long term

Dreieich, 06 September 2022. Biotest has received the operating licence for the 12th Cara Plasma plasmapheresis centre in the Czech Republic from the Czech health authority SUKL.

The centre is located in Pelhřimov in south-eastern Bohemia. In the state-of-the-art centre with 8 donor beds, plasma donors can donate plasma six days a week, Monday to Saturday.

"Thanks to this new plasma centre, ten new qualified jobs will be created in Pelhřimov," emphasises Roman Jakoubek, Managing Director of Cara Plasma Czech Republic.

Biotest is thus continuing the planned expansion of its own donor centres in Europe in order to significantly increase its plasma collection capacity.

"The opening of the centre is part of our strategy to increase the self-supply share of plasma at Biotest AG and to ensure the supply of patients worldwide," emphasises Henrik Oehme, Vice President of Plasma Service Europe GmbH.

The collected plasma is processed exclusively at Biotest AG in Dreieich. Audits conducted regularly in the Czech Republic ensure that the high legal and internal quality and safety requirements are met.



About human blood plasma

Human blood plasma is a raw material used to produce plasma derived products, which are used to treat various illnesses of the immune system, the blood system, as well as in emergency medicine. Biotest ranks as one of the world's sixth largest plasma protein product manufacturing groups. Biotest is one of the world's six largest manufacturers of plasma protein products.



About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,100 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.



IR contact

Dr Monika Buttkereit

Phone: +49-6103-801-4406


PR contact

Dirk Neumüller

Phone: +49-6103-801-269


Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany,


Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
Preference shares: securities’ ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate


This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.




06.09.2022 CET/CEST Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this